IMA is loading

The Road to Pharma Microbiology Congress 2022 presents “Aseptic fill finish robotized lines”, the free webinar live which will be given by IMA Life experts.

Post published on 15/09/2022

Aseptic fill finish robotized lines - Live webinar - 6 October 2022 at 10 AM (CEST)

Pharmaceutical companies and CDMOs need to be able to manage a wide range of different products and packagings including toxic/biological hazardous drugs.

The presentation will cover the IMA LIFE aseptic isolator and HVAC design and peculiarities, focusing on the features able to guarantee the fully compliance to current and future (new Annex 1) regulatory demand.

The presentation will also provide an overview of aseptic isolated line configuration in different production scenarios, underlining the design strategy to mix and balance sterility assurance and high containment.

Integrated with isolation technology, Injecta family, IMA latest-generation fill-finish machines for RTU components, will be presented.

Injecta implements advanced robotic technologies especially designed for flexibility, no-touch-transfer capabilities and maximum grade of sterility assurance.

Register now>>

SCHEDULED TIME: 10 – 11 am (CEST) – 6 October 2022
LANGUAGE: English
SPEAKERS

 
Stefano SpecchiaProduct Manager for Aseptic Processing Solutions

He is currently Product Manager for Aseptic Processing Solutions at IMA Life, a division of IMA S.p.A. His main focuses in his current position are on robotized machines for aseptic filling of RTU containers and on freeze dryer automatic loading/unloading systems. 
He joined IMA group in 2010 as Technical Engineer on automatic machines and then as Project Engineer of aseptic filling lines.

 

 

 

Giacomo Guidi, R&D for Isolation Technology

Giacomo Guidi works at R&D Isolation Technologies at IMA LIFE. He is working actively on fill-finishing projects, providing support in process design, innovative decontamination solutions and Pharma 4.0 digital transformation.

Register now for free

Get in touch

For any further information